[1] 中国医院协会药事管理专业委员会.质子泵抑制剂临床应用的药学监护[M].1版,人民卫生出版社,2013 : 6,27-29. [2] Ishizaki T,Horai Y. Review article:cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole [J]. Alimentary Pharmacology&Therapeutics,1999, 13 (S3) : 27-36. [3] Lind T, Rydberg L, Kyleback A. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastrooesophageal reflux disease[J]. Alimentary Pharmacology & Therapeutics,2000, 14(7) : 861-867. [4] Blume H, Donath F, Warnke A, et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors[J]. Drug Safety, 2006, 29(9) : 769-784. [5] 刘波, 姚鸿萍. 临床常用质子泵抑制剂的研究进展[J].西北药学杂志, 2014, 29(3) : 328-332. [6] 周尔文, 寿军, 李光武, 等.综合性医院门诊处方中常见CYP3A4抑制剂和诱导剂的代谢性相互作用调查[J].中国医药指南, 2013, 11(19) : 489-491. [7] 祝锡聪. 埃索美拉唑的临床应用与安全性[J].药物流行病学杂志, 2007, 16(4) : 215-217. [8] 李旭梅,涂厉标.奥美拉唑的化学配伍禁忌及药物相互作用[J].中国临床药学杂志,2009, 18(5) : 320-322. [9] 陈坚. 质子泵抑制剂的分类及药理学特性[J]. 上海医药, 2013, 34(21) : 3-7. [10] 彭华, 程泽能. 细胞色素P450-3A4相关的药物相互作用[J]. 中国临床药理学杂志, 2001, 17(5) : 379-385. [11] David W J, Clark, Johanna Strandell. Myopathy including polymyositis:a likely class adverse effect of proton pump inhibitors[J].European Journal of Clinical Pharmacology, 2006, 62(6) : 473-479. [12] Vlase L,Neag M, Popa A, et al.Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers:a prospective pilot study[J]. Current Therapeutic Research, 2010,71(6) : 360-368. [13] F.Itagaki, M.Homma, K.Yuzawa,et al. Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation[J]. Transplantation Proceedings, 2002, 34(7) : 2777-2778. [14] Calabresi L, Pazzucconi F, Ferrara S, et al. Pharmacokinetic interaction between omeprazole/pantoprazole and clarithromycin in healthy volunteers[J]. Pharmacological Reasearch, 2004, 49(5) :493-499. [15] Pilsgaard H D, Bjerregaard S T,Rix H M , et al. The potential drug-drug interaction between proton pump inhibitors and warfarin[J]. Pharmacoepidemiology & Drug Safety, 2015, 24 : 1337–1340. [16] Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy[J]. European Heart Journal, 2013, 34 : 1708–1713. [17] Gilard M, Arnaud B, Cornily J C, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study[J]. Journal of the American College of Cardiology, 2008, 51(3) : 256-260. [18] Zuern C S,Geisler T,Lutilsky N, et al. Effect of comedication with proton pump inhibitors(PPI) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy[J]. Thrombosis Research, 2010, 125 : e51-e54. [19] Troger U,Stotzel B,Martens-Lobenhoffer J, et al. Severe myalgia from an interaction between treatments with pantoprazole and methotrexate[J]. British Medical Journal, 2002, 324(7352) : 1 497. [20] Yucel E, Sancar M,Yucel A. Adverse drug reactions due to drug- drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method[J]. Expert Opinion on Drug Safety, 2016, 15(2) : 223-236. [21] Bouziana S D, Tziomalos K. Clinical relevance of clopidogrel-proton pump inhibitors interaction[J]. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2015, 6(2) : 17-21. [22] 魏春燕, 吴逢波. CYP450与药物相互作用[J].中国药业, 2014, 23(6) : 17-20. |